Related Experiment Video
Updated: Mar 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Discontinuation of Statins: What Are the Risks?
Joel C Marrs1, Matthew D Kostoff2
1Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Clinical Pharmacy, University of Colorado, Mail Stop C238, 12850 E. Montview Blvd., Room V20-2128, Aurora, CO, 80045, USA. joel.marrs@ucdenver.edu.
Insights
Statin therapy offers proven cardiovascular benefits. However, recent data suggest discontinuing statins may increase risks of heart attack and death, warranting careful consideration.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Statin therapy is widely recognized for its benefits in primary and secondary cardiovascular prevention.
- High rates of statin discontinuation are observed within the first year of treatment.
- National guidelines suggest limited benefit in specific populations like dialysis patients, heart failure with reduced ejection fraction, and individuals over 75 without atherosclerotic cardiovascular disease.
Purpose of the Study:
- To evaluate the implications of statin discontinuation on cardiovascular outcomes.
- To synthesize current evidence regarding the risks associated with stopping statin therapy.
Main Methods:
- Review of existing literature and recent studies on statin use and discontinuation.
- Analysis of data correlating statin discontinuation with cardiovascular events.
Main Results:
- Available data do not support statin discontinuation outside of specified guideline exclusions.
- Recent studies link statin discontinuation to an increased risk of myocardial infarction and cardiovascular death.
Conclusions:
- Discontinuation of statin therapy should be approached with caution.
- Careful consideration of individual patient data is crucial before altering statin treatment regimens.
Abstract:
The key benefits of statin therapy have been well established in both primary and secondary prevention cardiovascular patients. Many studies have shown a significant statin discontinuation rate within the first year of initiation whether for primary or secondary prevention. National guidelines for the management of dyslipidemia highlight the lack of benefit seen with statin therapy in patients with chronic kidney disease receiving dialysis, heart failure with reduced ejection fraction, and patients greater than 75 years of age without atherosclerotic cardiovascular disease. Available data outside of these patient populations do not support discontinuation of statin therapy. Recent studies support an association with statin discontinuation and increased risk of myocardial infarction and cardiovascular death. Based on the available data, discontinuation of statin therapy should be carefully considered.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics: Drug–Drug Interactions
Cholesterol: Significance and Regulation
Considering cholesterol and...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

